SEARCH:   Advanced

Blood, 16 April 2009, Vol. 113, No. 16, pp. 3666-3672. Prepublished online as a Blood First Edition Paper on November 19, 2008; DOI 10.1182/blood-2008-09-179341. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-09-179341v1 113/16/3666    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Derolf, A. R. Articles by Björkholm, M. Search for Related Content PubMed PubMed Citation Articles by Derolf, A. R. Articles by Björkholm, M. Related Collections Free Research Articles Myeloid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005 Åsa Rangert Derolf1, Sigurdur Yngvi Kristinsson1, Therese M.-L. Andersson2, Ola Landgren1,3, Paul W. Dickman2, and Magnus Björkholm1 1 Division of Hematology, Department of Medicine, Karolinska University Hospital, Solna and Karolinska Institutet, Stockholm, Sweden; 2 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; and 3 Division of Cancer Epidemiology and Genetics, Genetic Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD We evaluated survival patterns for all registered acute myeloid leukemia (AML) patients diagnosed in Sweden in 1973 to 2005 (N = 9729; median age, 69 years). Patients were categorized into 6 age groups and 4 calendar periods (1973-1980, 1981-1988, 1989-1996, and 1997-2005). Relative survival ratios were computed as measures of patient survival. One-year survival improved over time in all age groups, whereas 5- and 10-year survival improved in all age groups, except for patients 80+ years. The 5-year relative survival ratios in the last calendar period were 0.65, 0.58, 0.36, 0.15, 0.05, and 0.01 for the age groups 0 to 18, 19 to 40, 41 to 60, 61 to 70, 71 to 80, and 80+ years, respectively. Intensified chemotherapy, a continuous improvement in supportive care, and allogeneic stem cell transplantation are probably the most important factors contributing to this finding. In contrast, there was no improvement in survival in AML patients with a prior diagnosis of a myelodysplastic syndrome during 1993 to 2005 (n = 219). In conclusion, AML survival has improved during the last decades. However, the majority of AML patients die of their disease and age remains an important predictor of prognosis. New effective agents with a more favorable toxicity profile are needed to improve survival, particularly in the elderly. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. PRENKERT, B. UGGLA, E. TINA, U. TIDEFELT, and H. STRID Rapid Induction of P-Glycoprotein mRNA and Protein Expression by Cytarabine in HL-60 Cells Anticancer Res, October 1, 2009; 29(10): 4071 - 4076. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020